DOSE OF REALITY: FORBES: MAKING IT HARDER TO CHALLENGE BIG PHARMA’S PATENT THICKETS WOULD RAISE DRUG PRICES, UNDERMINE TRUE INNOVATION

Research Article Explores Negative Implications of Proposal to Restrict Key Mechanism for Challenging Egregious Abuse of the Patent System Avik Roy, president of The Foundation for Research on Equal

06-5-2024 Read More

DOSE OF REALITY: FORBES: HOW BIG PHARMA STIFLES COMPETITION WITH PRODUCT HOPPING

Research Column Explores Case Study in Common Patent Abuse Tactic That Negatively Impacts Consumers, Extends Monopolies and Keeps Drug Prices High A new research column in Forbes this week explores

05-23-2024 Read More

THEY SAID IT!: LAWMAKERS ROAST BIG PHARMA’S PATENT ABUSE, CALL FOR ACTION ON BIPARTISAN SOLUTIONS TO HOLD THE PHARMACEUTICAL INDUSTRY ACCOUNTABLE

Senate Judiciary Committee Puts Spotlight on Big Pharma’s Anti-Competitive Tactics that Extend Monopolies and Keep Drug Prices High On Tuesday, the U.S.

05-22-2024 Read More

DOSE OF REALITY: BIG PHARMA’S PATENT ABUSE BLOCKS COMPETITION IN THE PRESCRIPTION DRUG MARKET, KEEPS DRUG PRICES HIGH

Senate Hearing Offers Opportunity to Highlight Market-Based Solutions to Hold Big Pharma Accountable for Anti-Competitive Tactics That Cost Patients and Taxpayers Billions of Dollars The U.S. Senate

05-21-2024 Read More

DOSE OF REALITY: STUDY FINDS NEARLY THREE-QUARTERS OF BIG PHARMA’S PATENTS ON TOP-SELLING DRUGS FILED AFTER FDA APPROVAL

Analysis Showcases Egregious Scale of Big Pharma’s Patent Thickets on Blockbuster Products, Including Nearly 1,500 Patent Applications on Just Ten Drugs A new study, published in JAMA Network,

05-16-2024 Read More

DOSE OF REALITY: IQVIA REPORT SHOWS HOW BIG PHARMA’S EGREGIOUS PRICING PRACTICES DRIVE INCREASED PRESCRIPTION DRUG SPENDING

Analysis Shows Price Hikes Outpacing Inflation, Rising Launch Prices and Egregious GLP-1 Weight Loss Pricing Fueled 10 Percent Climb in U.S. Drug Spending A report released Tuesday from the IQVIA

05-10-2024 Read More

BIG PHARMA EARNINGS WATCH: ELI LILLY, NOVO NORDISK, ABBVIE, AMGEN, GLAXOSMITHKLINE AND PFIZER

Repeated Price Hikes and Egregious Prices on GLP-1 Weight Loss Drugs Boost Profits for Big Pharma Giants at the Expense of American Patients Over the last week

05-6-2024 Read More

DOSE OF REALITY: BIOSIMILAR COMPETITION GENERATES SIGNIFICANT SAVINGS FOR PATIENTS AND THE U.S. HEALTH CARE SYSTEM

Reports Find Biosimilars Have Lower Prices Than Brand Name Biologics, Result in Lower OOP Costs for Patients, and Produce Billions of Dollars in Savings Big Pharma deploys a full suite

05-2-2024 Read More

CSRXP APPLAUDS EXPANDED FTC CRACK DOWN ON BIG PHARMA’S SHAM PATENTS IN THE ORANGE BOOK

Commission Builds on Previous Action by Targeting More Than 300 Patents, Including on Blockbuster GLP-1 Weight Loss Drugs Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP)

04-30-2024 Read More

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.